Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

The Partnership to Fight Infectious Disease has put out a timely notice about support for vaccines. Forty-five minutes before ...

When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

“Awareness initiatives like Thyroid Awareness Month play a crucial role in promoting early screening and intervention,” the ...

The Trump administration’s executive order pausing foreign aid programs has sent crash waves through relief organizations ...

Two attempts by Johnson & Johnson to resolve approximately 60,000 talcum powder lawsuits through bankruptcy courts have ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...